Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Belite Bio stock target raised to $80 at Benchmark | 1 | Investing.com | ||
21.03. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
18.03. | Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials | 2 | Benzinga.com | ||
18.03. | Belite Bio stock holds $100 target post-results | 1 | Investing.com | ||
BELITE BIO Aktie jetzt für 0€ handeln | |||||
17.03. | Belite Bio GAAP EPS of -$0.32 misses by $0.01 | 1 | Seeking Alpha | ||
17.03. | Belite Bio, Inc Q4 Loss Increases, Misses Estimates | 1 | RTTNews | ||
17.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
17.03. | Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | 1 | GlobeNewswire (USA) | ||
17.03. | Belite Bio, Inc: Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 69 | GlobeNewswire (Europe) | Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without... ► Artikel lesen | |
11.03. | Belite Bio, Inc: Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
27.02. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
27.02. | Belite Bio, Inc: Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects | 101 | GlobeNewswire (Europe) | An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned... ► Artikel lesen | |
06.02. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
06.02. | Belite Bio to raise $15M via direct offering | 4 | Seeking Alpha | ||
06.02. | Belite Bio, Inc: Belite Bio Announces Registered Direct Offering of $15 Million | 1 | GlobeNewswire (USA) | ||
27.01. | Belite Bio files for automatic mixed securities shelf | 1 | Seeking Alpha | ||
30.11.24 | Belite Bio (NASDAQ:BLTE) Shares Down 3.4% - Time to Sell? | 1 | MarketBeat | ||
16.11.24 | Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 13.5% | 2 | MarketBeat | ||
14.11.24 | Belite Bio stock soars to all-time high of $84.2 amid robust gains | 1 | Investing.com | ||
14.11.24 | Belite Bio-Aktie erreicht Rekordhoch von 84,20 US-Dollar | 2 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANGAMO THERAPEUTICS | 0,725 | -4,47 % | Sangamo Therapeutics Aktie: Interessante Fakten zusammengetragen | Sangamo Therapeutics bleibt ein zentraler Akteur in der Biotechnologiebranche und navigiert durch eine komplexe Landschaft aus Innovation und finanziellen Herausforderungen. Das für seine Pionierarbeit... ► Artikel lesen | |
ARGENX | 542,60 | -1,06 % | argenx SE: argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update | $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA... ► Artikel lesen | |
AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
PROTALIX BIOTHERAPEUTICS | 2,370 | +0,08 % | Amended: Protalix Annual Earnings Fall | JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for... ► Artikel lesen | |
ENZO BIOCHEM | 0,356 | +0,56 % | Enzo Biochem, Inc.: Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX | FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced its intention to voluntarily delist its common stock from The New York... ► Artikel lesen | |
QUANTERIX | 6,535 | 0,00 % | Quanterix Corp - 8-K, Current Report | ||
LEXEO THERAPEUTICS | 3,970 | 0,00 % | H.C. Wainwright maintains Buy on Lexeo stock, $23 target | ||
TEMPUS AI | 47,480 | 0,00 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
BIONTECH | 82,25 | -5,35 % | Bayer, Vidac Pharma, BioNTech - Niederschläge und neue Maßstäbe | Glyphosat und kein Ende. Die Übernahme des US-amerikanischen Agrarunternehmens Monsanto durch Bayer im Jahr 2018 entwickelt sich weiterhin zum Milliardengrab, erneut entschied ein Gericht gegen die... ► Artikel lesen | |
PORTAGE BIOTECH | 9,630 | 0,00 % | Pre-market Movers: Portage Biotech, XTI Aerospace, Marblegate Acquisition Corp., Cricut, Ecarx Holdings | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.25 A.M. ET).In the Green Portage Biotech Inc (PRTG) is up over 155% at $12.09.
Bowen... ► Artikel lesen | |
QIAGEN | 36,670 | -0,35 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
EVOTEC | 5,980 | -0,33 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,785 | 0,00 % | Recursion Pharmaceuticals CEO verkauft Aktien im Wert von 836.986 US-Dollar | ||
SPRINGWORKS THERAPEUTICS | 47,040 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BB BIOTECH | 32,350 | -0,92 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen |